Cargando…

Refractory Psoriasis Vulgaris with Itching Successfully Treated with the Anti-interleukin-17A Antibody Secukinumab: A Case of Secondary Failure of Other Biologic Agents

Detalles Bibliográficos
Autores principales:	Kurosaki, Yuko, Takamori, Kenji, Suga, Yasushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2017
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527742/ https://www.ncbi.nlm.nih.gov/pubmed/28794572 http://dx.doi.org/10.4103/ijd.IJD_97_17

Ejemplares similares

Molecular and Cellular Mechanisms of Itch in Psoriasis
por: Komiya, Eriko, et al.
Publicado: (2020)

Successful treatment of generalized pustular psoriasis with secukinumab: a report of two cases
por: Sun, Zhi-Lin, et al.
Publicado: (2020)

Secukinumab - First in Class Interleukin-17A Inhibitor for the Treatment of Psoriasis
por: Godse, Kiran
Publicado: (2017)

Relationship between the Degrees of Itch and Serum Lipocalin-2 Levels in Patients with Psoriasis
por: Aizawa, Norie, et al.
Publicado: (2019)

Successful use of secukinumab in pustular psoriasis
por: Yeung, Jensen, et al.
Publicado: (2016)

Effects of adalimumab and secukinumab on comorbidities associated with metabolism in patients with plaque psoriasis
por: Zhang, Si, et al.
Publicado: (2022)

Repigmentation and new growth of hairs after anti–interleukin-17 therapy with secukinumab for psoriasis
por: Rongioletti, Franco, et al.
Publicado: (2018)

Secukinumab for Recalcitrant Chronic Plaque Psoriasis in a 9 Year Old Child
por: Shruthi, R, et al.
Publicado: (2021)

Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris
por: Palazzo, Giovanni
Publicado: (2020)

Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery following Secukinumab Administration
por: Frustaci, Andrea, et al.
Publicado: (2023)

Real-world investigation of the efficacy and safety of secukinumab for psoriasis treatment in a Chinese population
por: Zeng, Jing-Xin, et al.
Publicado: (2021)

Interleukin-17A Inhibitor Secukinumab Treatment in HIV-Positive Psoriasis Patient: A Case Report
por: Gong, Jian, et al.
Publicado: (2022)

Secukinumab: The Anti-IL-17A Biologic for the Treatment of Psoriasis
por: Fargnoli, Maria Concetta
Publicado: (2019)

Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real‐world evidence in Japan
por: Fujita, Hideki, et al.
Publicado: (2020)

Successful treatment of adalimumab-resistant palmoplantar pustulosis with secukinumab: a case report
por: Li, Qing-Yang, et al.
Publicado: (2020)

Effectiveness and safety of secukinumab in Chinese patients with plaque psoriasis in a clinical practice setting: a pilot study
por: Zhu, Si-Man, et al.
Publicado: (2020)

Alopecia Diffusa while Using Interleukin-17 Inhibitors against Psoriasis Vulgaris
por: Yajima, Makiko, et al.
Publicado: (2019)

Itch in Psoriasis
por: Grattan, Clive E. H.
Publicado: (1985)

A Review of the Safety of Interleukin-17A Inhibitor Secukinumab
por: Eshwar, Vishnu, et al.
Publicado: (2022)

Dhobies' Itch
por: Wade-Brown, F.
Publicado: (1898)

Case of Itching
por: Waghray, K. N.
Publicado: (1918)

Water-Itch
por: Dalgetty, A. B.
Publicado: (1898)

Secukinumab in Generalized Pustular Psoriasis
por: Madanagobalane, Shraddha
Publicado: (2018)

Effects of Dupilumab on Itch-Related Events in Atopic Dermatitis: Implications for Assessing Treatment Efficacy in Clinical Practice
por: Kishi, Ryoma, et al.
Publicado: (2023)

Juvenile Pityriasis Rubra Pilaris in a 4-year-old Child Treated Successfully with Secukinumab
por: Albela, Henrietta, et al.
Publicado: (2022)

Successful secukinumab treatment in focal segmental glomerulosclerosis associated with plaque psoriasis
por: Cao, Zhiqiang, et al.
Publicado: (2022)

Treatment Options for Troublesome Itch
por: Toyama, Sumika, et al.
Publicado: (2022)

A Case of Psoriasis Vulgaris Aggravated with Atorvastatin, Aided by Concomitant Cyclosporine
por: Ardeshna, Kenit P, et al.
Publicado: (2017)

A Case of Cutaneous T-cell Lymphoma, Masquerading as Psoriasis, Was Given Etanercept and Secukinumab: Emphasizing the Need for Biopsy Confirmation before Starting Biologics
por: De, Abhishek, et al.
Publicado: (2017)

CD11b(+) cells markedly express the itch cytokine interleukin‐31 in polymorphic light eruption
por: Patra, V., et al.
Publicado: (2019)

Linear porokeratosis with severe itch accompanied by lesional upregulation of interleukin 31, thymic stromal lymphopoietin, and periostin
por: Hashimoto, Takashi, et al.
Publicado: (2021)

Secukinumab on Refractory Lupus Nephritis
por: Costa, Rita, et al.
Publicado: (2021)

Recalcitrant annular pustular psoriasis associated with psoriatic arthritis successfully treated with secukinumab
por: Herrero-Moyano, María, et al.
Publicado: (2018)

Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with ustekinumab
por: Petty, Amy J., et al.
Publicado: (2020)

Erythrodermic psoriasis and palmoplantar hyperkeratosis successfully treated with secukinumab: a case report
por: Carriero, Martino
Publicado: (2022)

Successful Treatment of Recurrent Pustular Psoriasis of Pregnancy with Secukinumab: A Case Report
por: LIU, Na, et al.
Publicado: (2020)

Case report: Successful treatment of acute generalized pustular psoriasis of puerperium with secukinumab
por: Xue, Gao, et al.
Publicado: (2022)

Mechanisms and Management of Itch in Dry Skin
por: MONIAGA, Catharina Sagita, et al.
Publicado: (2020)

Real-world clinical experience of secukinumab in Chinese patients with psoriasis in real-world practice: a 36-week single-center study of 24 patients
por: Zhang, Jing, et al.
Publicado: (2020)

Connective Tissue Growth Factor Neutralization Aggravates the Psoriasis Skin Lesion: The Analysis of Psoriasis Model Mice and Patients
por: Hayakawa, Kunihiro, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5mejnk31fenlnns1qadmok7u3m